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ABSTRAK
Resistensi bakteri terhadap antibiotik merupakan salah satu masalah yang sangat serius di seluruh 
dunia yang berdampak pada meningkatnya angka morbiditas dan mortalitas, salah satunya adalah akibat 
Enterobacteriaceae penghasil ESBL. Meskipun demikian, informasi mengenai penegakan diagnosis dan 
penatalaksanaan infeksi ESBL-E masih terbatas. Deteksi ESBL-E memerlukan beberapa tahap yang cukup sulit 
dan memerlukan waktu yang lama. Diagnosis dan penatalaksanaan infeksi akibat ESBL-E menjadi semakin 
sulit karena keterbatasan metode diagnosis yang ada dan pilihan antibiotik yang dapat digunakan, bersamaan 
dengan subtipe ESBL yang terus berkembang melalui proses mutasi yang beragam. Artikel ini bertujuan untuk 
memberikan gambaran mengenai keadaan terkini tentang infeksi ESBL-E yang terfokus pada diagnosis dan 
penanganan infeksi tersebut melalui pembahasan beberasa studi mengenai masalah ini.
Kata kunci: resisten multi obat, ESBL, diagnosis, penatalaksanaan.
ABSTRACT
Bacterial resistance to antibiotics is a serious problem worldwide that affect the increment of morbidity 
and mortality rate; Enterobacteriaceae producing ESBL is one of the causes. However, there are still limited 
information regarding diagnosis and management of ESBL-E infection. Detection of ESBL-E requires certain 
steps that are problematic and time consuming. Diagnosis and management of ESBL-E infection have become 
more and more challenging due to limited diagnostic method available and choice of antibiotics that may be 
used, along with growing subtyped of ESBL through various of mutations. This article is aimed to give an 
overview on current situation of ESBL-E infections, with a focus on diagnosis and management of such infection 
by reviewing several recent studies on related issue.
Keywords: multi-drug resistant, ESBL, diagnosis, management.
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INTRODUCTION
Bacterial resistance to antibiotics is a serious 
problem worldwide. Until recently, many cases 
of resistance towards antibiotics are known due 
to methicillin-resistant Staphylococcus aureus 
(MRSA), vancomycin resistant Enterococci 
(VRE), penicillin-resistance Pneumococci, 
carbapenem-resistance Acinetobacter baumanni, 
multi-resistant Mycobacterium tuberculosis, 
and Enterobacteriaceae producing extended-
spectrum β-lactamase (ESBL).1
Production of ESBL is an important 
mechanism causing resistance towards 3rd 
generation of cephalosporin, such as ceftazidime, 
ceftriaxone, and cefotaxime, which is commonly 
used, for empirical therapy of antibiotics. 
The growing prevalence of infection due 
to Enterobacteriaceae producing ESBL 
(ESBL-E) cause challenge in treating nosocomial 
infection that usually treated empirically with 
cephalosporin and fluoroquinolon. Delayed 
diagnosis and management are related to high 
mortality, hospital cost and length of stay in the 
hospital.2,3
Since more than 70% of world populations 
live in the Asia-Pacific region, antibiotic 
resistance in Asia is also considered as a 
global problem. The Study for Monitoring 
Antimicrobial Resistance Trends (SMART) 
which monitor the pattern of antibiotic resistance 
in intra-abdominal infection since 2002 and 
urinary tract infection since 2009 until 2011, 
found the main multi-resistant bacteria causing 
infection are Escherichia coli and Klebsiella 
pneumoniae with the prevalence of 47.8% and 
14.5% respectively in intra-abdominal infection, 
whereas in urinary tract infection are 44.3% 
and 11.8% respectively. Moreover, the SMART 
study also obtained that highest prevalence of 
ESBL-E infection is in Asia, which is more than 
40%, followed by Latin America and the Middle 
East. The SMART study also showed increasing 
pattern of infection by ESBL-E prevalence in 
Asia.4,5
The use of broad-spectrum antibiotics, 
especially third generation of cephalosporin and 
fluoroquinolon leads to the growth of ESBL-E 
in hospital and associated with high treatment 
failure and mortality. Early control of ESBL-E 
in sepsis patients due to nosocomial infection 
and adequate treatment is essential in patients’ 
management.2 This review will discuss about the 
diagnosis and management of ESBL.
DEFINITION OF ESBL
Extended spectrum β-lactamase (ESBL) is 
an enzyme produced by certain bacteria causing 
them to become resistant to several antibiotics 
including third generation of cephalosporin and 
aztreonam. This enzyme works by hydrolyzing 
β-lactam ring in β-lactam antibiotics (BL). It is 
carried in the chromosomes of those particular 
bacteria and transferred to other populations 
of bacteria through plasmid. There are several 
ESBL-E known today, including Klebsiella 
pneumoniae (ESBL-KP) and Escherichia coli 
(ESBL-EC). The ESBL-E infection firstly found 
was an infection by K. Pneumonia in Germany 
in the year of 1983 and spread to all Europe as 
well as America. In Asia, the first infection was 
found in China in 1988.6-8
CLASSIFICATION OF ENZYME Β-LACTAMASE
There are many classification schemes 
available for enzyme β-lactamase, however the 
most commonly used are the Ambler classification 
and the Bush-Jacobsky classification. Ambler 
classification, was first communicated in 1991, 
categorized ESBL into 4 classes, that are A, B, 
C, and D based on their amino acid structure, 
where class A, C and D have an active side of 
serine-β-lactamase and class B have an active 
side of metallo-β-lactamase.8,9
The Bush-Jacobsky-Mendeiros was first 
introduced in 1989, expanded on 1995 and 
renewed to become Bush-Jacobsky classification 
in the year of 2009, where β-lactamase enzyme 
is categorized into 4 different groups, presented 
in Table 1. The first group is cephalosporinase 
or AmpC, also known as Ambler class C. It is 
more active towards cephalosporin compared 
to benzilpenicillin and usually resistant to 
clavulanate acid inhibition, also active towards 
cephamicin such as cephotixin, and high affinity 
toward aztreonam.9
The second group is also known as serine-β-
lactamase. It is the largest group of β-lactamase 
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Table 1. Enzyme β-lactamase classification9
Bush-Jacoby 
group (2009)
Bush-
Jacoby-
Medeiros 
group (1995)
Molecular 
class 
(subclass)
Distinctive 
substrate(s)
Inhibited by
Defining 
characteristic(s)
Representative 
enzyme(s)CA or 
TZBa EDTA
1 1 C Cephalosporins No No Greater hydrolysis 
of cephalosporins 
than benzylpenicillin; 
hysrolyzes 
cephamycins
E.coli AmpC, 
P99, ACT-1, 
CMY-2, FOX-
1, MIR-1
1e NIb C Cephalosporins No No Increased hydrolysis 
of ceftazidime and 
often other oxymino-
b-lactams
GC1, CMY-37
2a 2a A Penicillins Yes No Greater hydrolysis of 
benzylpenicillin than 
cephalosporins
PC1
2b 2b A Penicillins, 
early 
cephalosporins
Yes No Similar hydrolysis of 
benzylpenicillin and 
cephalosporins
TEM-1, TEM-
2, SHV-1
2be 2be A Extended-
sepctrum 
cephalosporins, 
monobactams
Yes No Increased hydrolysis 
of oxymino-b-
lactams (cefotaxime, 
ceftazidime, 
ceftriaxone, cefepime, 
aztreonam)
TEM-3, SHV-2, 
CTX-M-15, 
PER-1, VEB-1
2br 2br A Penicillins No No Resistance to 
clavulanic acid, 
sulbactam, and 
tazobactam
TEM-30, SHV-
10
2ber NI A Extended-
spectrum 
cephalosporins, 
monobactams
No No Increased hydrolysis 
of oxymino-b-
lactams combined 
with resistance to 
clavulanic acid, 
sulbactam, and 
tazobactam
TEM-50
2c 2c A Carbenicillin Yes No Increased hydrolysis 
of carbenicillin
PSE-1, CARB-
3
2ce NI A Carbenicillin, 
cefepime
Yes No Increased hydrolysis 
of carbenicillin, 
cefepime, and 
cefpirone
RTG-4
2d 2d D Cloxacillin Variable No Increased hydrolysis 
of cloxacillin or 
oxacillin
OXA-1, OXA-
10
2de NI D Extended-
spectrum 
cephalosporins
Variable No Hydrolyzes cloxacillin 
or oxacillin and 
oxymino-b-lactams
OXA-11, OXA-
15
2df NI D Carbapenems Variable No Hydrolyzes cloxacillin 
or oxacillin and 
carbapenems 
OXA-23, OXA-
48
2e 2e A Extended-
spectrum 
cephalosporins
Yes No Hydrolyzes 
cephalosporins. 
Inhibited by clavulanic 
acid but not 
aztreonam
CepA
2f 2f A Carbapenems Variable No Increased hydrolysis 
of carbapenems, 
oxymino-b-lactams, 
cephamycins
KPC-2, IMI-1, 
SME-1
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enzyme due to its increasing prevalence in 
the last 20 years. It belongs to Ambler class 
A and D. The third group is also known as 
metallo-β-lactamase (MBL), which has unique 
structures, and functions, that requires zinc in 
their active site, and have the ability to hydrolyze 
carbapenem. However, nowadays several serine-
β-lactamase also have this ability. The difference 
between them is that MBL has low monobactam 
hydrolyzing ability and cannot be inhibited by 
clavulanate acid and tazobactam. According to 
Ambler classification, they belong to class B. The 
fourth group of ESBL is present in the previous 
classification of 1995 but has been omitted in the 
latest scheme. This enzyme might be categorized 
into different classification if sufficient data is 
available.8,9
TYPES OF ESBL
The type of ESBL that is commonly found is 
Temoneira (TEM). About 90% of E. coli, which 
are resistant to ampicillin, occurred due to the 
production of TEM-1. This type has the ability 
to hydrolyze penicillin and first generation of 
cephalosporin but not cephalosporin oxymino. 
Although it is usually found in E. coli and K. 
pneumonia, frequency of TEM type β-lactamase 
is also increasing in other gram-negative bacteria. 
Until recently, there are 140 TEM type is known. 
The second type is Sulfhydryl variable (SHV) 
whose 68% of its amino acid is similar to TEM 
type. Most commonly found in K. pneumonia is 
SHV-1 that cause resistance towards penicillin, 
tigecycline and piperacillin but not cephalosporin 
oxymino. There are 60 SHV type known so far 
in Europe, America and in the whole world. 
The TEM-1 and SHV-1 type have the ability 
to inactivate ampicillin, and some of them may 
experience further mutation that will lead to 
expansion of β-lactamase activity. This explains 
why there are other types of TEM and SHV that 
also cause the third generation of cephalosporin 
and aztreonam inactivation.10-13
The Cefotaxime hydrolyzing capabilities 
(CTX) type has stronger ability in hydrolyzing 
cefotaxime, and may be inhibited by tazobactam 
as β-lactamase inhibitor. There are more than 80 
CTX type known so far. The CTX-M enzyme 
is not limited to nosocomial infection only but 
have the potency to spread in the community 
(usually by E. coli) and this has become a 
public health problem. According to a survey in 
2000, the prevalence of ESBL-E in community 
of European countries has increased. A study 
by Ben-Ami et al14 in Israel found that 14% of 
ESBL infection have community onset. This 
study also showed that there was an increased 
risk of infection in nursing homes. Furthermore, 
Rodriguez-Bano et al15 did an analysis between 
the uses of BL antibiotics and β-lactam inhibitors 
(BLI) as a combination compared to carbapenem 
in treating infections caused by ESBL-EC in the 
year of 2011 towards 103 Spanish patients, and 
found that 51% cases occurred in the community 
Table 1. Enzyme β-lactamase classification9
Bush-Jacoby 
group (2009)
Bush-
Jacoby-
Medeiros 
group (1995)
Molecular 
class 
(subclass)
Distinctive 
substrate(s)
Inhibited by
Defining 
characteristic(s)
Representative 
enzyme(s)CA or 
TZBa EDTA
3a 3 B (B1) Carbapenems No Yes Broad-spectrum 
hydrolysis including 
carbapenems but not 
monobactams
IMP-1, VIM-1, 
CerA, IND-1
B (B3) L1, CAU-1, 
GOB-1, FEZ-1
3b 3 B (B2) Carbapenems No Yes Preferential hydrolysis 
of carbapenems
CphA, Sfh-1
NI 4 Unknown
a CA, clavulanic acid; TZB, tazobactam
b NI, not included.
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due to CTX-M. Moreover, Severin et al16 did a 
research about the characteristics of ESBL-EC 
and ESBL-KP infections in Surabaya and found 
that the prevalence of CTX-M-15 in ESBL-EC 
is 94.5% and ESBL-KP is 55.6%.11-12
Oxacillin hydrolyzing capabilities (OXA) 
β-lactamase is a less commonly found type, 
and has different characteristics from TEM 
as well as SHV since it belongs to Ambler 
class D. This type has the ability to hydrolyze 
oxacilin and cloxacillin, and cannot be inhibited 
by clavulanate acid. It is mainly found in P. 
aeruginosa, mostly in Turkey and France, but 
also present in other gram-negative bacteria 
such as 1-10% E. coli producing OXA-1. 
Several other ESBL that is transmitted through 
plasmid, such as Pseudomonas extended 
resistant (PER), Vietnam ESBL (VEB), Guiana 
extended-spectrum (GES) and integron-borne 
cephalosporinase (IBC) are rarely found and 
have very limited transmission.10-12
ESBL MECHANISMS OF RESISTANCE
Bacteria may become resistance to β-lactam 
antibiotics through several mechanisms. Most 
commonly found is through the destruction by 
β-lactamase enzyme in the periplasm of gram-
negative bacteria. This enzyme has higher 
affinity towards antibiotics than antibiotics to 
their target. The binding of this enzyme will 
cause β-lactam ring to hydrolyze. The gene 
coding β-lactamase is found in the chromosomes 
and extra-chromosomes, and usually a mobile 
element. This ESBL resistance may be acquired 
in a mobile genetic element (such as in K. 
pneumoniae and E. coli) or in an immobile 
genetic chromosomes (in Enterobacter species), 
and have the ability to hydrolyze penicillin and 
cephalosporin. One of the strategy to counteract 
this mechanism is by using inhibitors that bind 
to these enzyme, however inhibitors such as 
clavulanate acid, sulbactam and tazobactam do 
not bind to all β-lactamase in the chromosomes, 
hence cannot fully prevent inactivation of BL 
antibiotics by this enzyme. There is no BL/BI 
combination known so far has the ability to 
inhibit all β-lactamase enzyme.17,18
Other mechanisms include coupling in 
gram-negative bacteria where there is reduced 
membrane permeability with fast antibiotics 
reflux from periplasm to exterior of the cell. 
This mutation will cause decreased amount 
of BL antibiotics that goes into the cell, along 
with increased amount of channels pumping out 
the antibiotics outward. This mechanism also 
happens in the resistance of ESBL-E towards 
quinolone and aminoglycoside.18
DETECTION OF ESBL
Identification of ESBL-E is a problem in 
hospitals and laboratory facilities despite its 
importance in therapeutic approach and infection 
control to prevent their spread. Most guidelines 
recommend specimen screening based on 
reduced sensitivity towards cephalosporin and 
followed by one of the tests available to confirm 
the presence of ESBL-E. However, it is still not 
known which method should be used.19
According to National Committee for 
Clinical Laboratory Standards (NCCLS); 
which is changed into Clinical and Laboratory 
Standards Institute (CLSI) in 2005, mentioned 
that ESBL screening should be routinely done. 
Recommendation by CLSI shows that ESBL 
detection is consists of two steps, the first is 
screening for reduced sensitivity to certain 
antibiotics used such as cefotaxime, ceftriaxone, 
ceftazidime, or aztreonam. The next step is to 
do a confirmatory test only if positive screening 
result is found. The aim of confirmatory test 
is to detect hydrolyzing potential by ESBL 
towards antibiotics that are used in screening 
in the presence of BLI. Several type of tests 
are recommended by CLSI, however until now 
there is no gold standard examination to detect 
ESBL.20-22
Screening test of ESBL may be done using 
Vitek, and positive result is when there is a 
resistance towards cephalosporin and aztreonam. 
Positive or negative result is evaluated using 
Advanced Expert System. Moreover, Kirby-
Bauer disks, according to CLSI recommendation, 
can also do screening test.23,24
Confirmatory test may be done using double-
disk synergy test (DDST), combination disk 
method, or E-test ESBL strip. The DDST test is 
performed on agar with a 30 μg disk of cefotaxime 
(and⁄or ceftriaxone and⁄or ceftazidime and⁄or 
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aztreonam) and a disk of 10μg of clavulanate 
acid positioned at a distance of 30 mm (centre 
to centre). The test is considered as positive 
when a decreased susceptibility to cephalosporin 
is combined with a clear-cut enhancement of 
the inhibition zone in front of the clavulanate 
acid-containing disk (Figure 1). Whereas the 
evaluation of combination disk method is by 
measuring the inhibition area around disk 
containing cephalosporin and disk containing 
cephalosporin and clavulanate acid. Usually both 
disks are located at a distance of ≥5 mm (centre 
to centre), and positive result is when the area 
enlarged until 50% (Figure 2). Confirmatory test 
may also be done using E-test ESBL strip. Two-
sided strips are used in this method, containing 
cefotaxime, cefazidime or cefepim, either 
alone at one end of the strip, or combine with 
clavulanate acid on the other end. The E-test 
ESBL strip is considered as positive when there 
is a phatom zone in the lowest concentration 
of antibiotic with clavulanate acid or when the 
minimum inhibitory concentrations (MIC) is 
reduced by more than two-fold in the presence 
of clavulanate acid (Figure 3).23
A study by Garrec et al19 in a hospital in 
France, compared different phenotype method 
in the detection of ESBL-E. It was mentioned 
that Vitek is considered as a routine method in 
the detection of ESBL with sensitivity 92-93% 
and low specificity that is 50-79%. However, 
E-test has the sensitivity of 71-73% in testing 
cefotaxime and ceftazidim, and 90% for cefepime. 
Another method is combination disk methods 
with sensitivity 100% in testing cefotaxime and 
cefepim towards ESBL-E. Double-disk synergy 
method has better sensitivity but the distance of 
how the disks should be positioned still need 
recommendation by microbiologists.
Phenotype confirmatory tests, as mentioned 
before, cannot identify specific enzymes causing 
the production of ESBL. Therefore, genotype 
confirmatory tests is also important, and may 
be done using polymerase chain reaction (PCR) 
followed by sequencing to differ variants of 
those specific enzymes. Several other methods 
include PCR with restriction fragment length 
polymorphism analysis (PCR-RFLP) and PCR 
with single-strand conformational polymorphism 
analysis (PCR-SSCP). Nevertheless, subtypes 
of ESBL continue to grow hence these methods 
have develop limitation; which made detection 
of ESBL become complex and difficult due to 
variety of mutation process.
RISK FACTORS OF ESBL COLONIZATION 
AND INFECTION
Infections due to ESBL-E are usually 
nosocomial and most commonly found in 
intensive care units (ICUs), and related to the 
length of stay, increased cost and mortality. 
Several risk factors mentioned by Park et 
al26 in their study on all bacteremia patients 
in Korean hospitals since January 2005 until 
Figure 1. Double-disk synergy test (DDST) method7
Figure 2. Combination disk method24
Figure 3. E-test ESBL strip7
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March 2009 include geriatrics, diseases such 
as liver cirrhosis and malignancy that usually 
need long hospital care, airway and urinary 
tract infections, use of catheter and naso-gastric 
tube (NGT), severe sepsis and use of third 
generation of cephalosporin and quinolone in 
the last 3 months during hospital stay. Similar 
things also communicated by Muro et al27 in their 
research among 90 patients in Mexico with ESBL 
infections known from their blood culture results, 
and found that several risk factors causing this 
infection are the use of catheter and intravenous 
line, hospital length of stay more than 15 days, 
underwent surgery, and use of cephalosporin.
Whereas in a study by Freeman et al28 of 
206 patients with culture result of ESBL-EC 
and ESBL-KP in 3 different hospitals in New 
Zealand from 2009 until 2011, obtained that 
patients experienced ESBL-EC usually occur 
due to community infection or with chronic 
pulmonary infection in high prevalence country. 
On the other hand, infection due to ESBL-KP is 
usually related to ICU admission, surgery and 
transmission within health care facilities.
Recently, several cases of ESBL-E in the 
community have been reported. Comparison 
of the characteristics and risk factors due to 
ESBL-E in the community and nosocomial are 
summarized in Table 2.25
MANAGEMENT OF ESBL INFECTIONS
Until recently, choices of antibiotics available 
to treat ESBL-E infections are still limited. 
According to European antimicrobial resistance 
survey in 2011 from culture results that the 
prevalence of third generation of cephalosporin 
in E. coli and K. pneumoniae are 9.1% and 
30.1%; in ESBL-EC is 85-100% and ESBL-KP 
is 62.5-100%. Resistance of E. coli towards 
carbapenem, quinolone and aminoglycosides 
are 0.04%, 20.9% and 9.3% respectively; 
whereas resistance of K. pneumoniae towards 
carbapenem, quinolone and aminoglycosides are 
9.1%, 30.5%, and 26.2%, respectively. Because 
resistance towards first line of antibiotics 
treatment is increasing, therefore choice of 
empirical antibiotic treatment has become more 
difficult. Empirical antibiotic treatments should 
be based on antibiogram in different institution 
and usually varies from one hospital to another 
in different city and countries.25,29
Several studies mentioned that cephalosporin 
still can be used because ESBL type TEM 
and SHV have low MIC towards cefotaxim. 
However, CLSI recommends that all ESBL-E 
should be considered as resistant to cephalosporin 
without considering their MIC because the use of 
cephalosporin is related to high treatment failure 
and mortality. This is occurred due to inoculum 
effect in bacteria with the ability to destroy the 
antibiotics. When bacteria die and destroy the 
antibiotics at the same time, cellular enzyme 
will be released and may reduce antibiotics 
concentration. In vitro test to evaluate bacteria’s 
ability to counteract antibacterial activity by BL 
antibiotics is determined by 2 factors, which 
are antibiotics intrinsic activity toward bacteria 
tested and antibiotic susceptibility to hydrolyze 
β-lactamase enzyme. In general, the higher the 
inoculum effect, the easier certain antibiotics to 
be hydrolyzed by ESBL.30,31
Table 2. Characteristics of ESBL-E infections25
Onset Community acquired Hospital acquired
Organism Escherichia coli Klebsiella spp
Type of ESBL CTX-M (mostly CTX-M15) Mostly SHV and TEM
Infection Majority is urinary tract infection Airway and intra abdominal infection
Susceptibility Resistance to all penicillin and cephalosporin, also 
several other antibiotics including fluoroquinolone
Resistance to all penicillin and cephalosporin, 
also several other antibiotics including 
fluoroquinolone
Risk factors Recurrent urinary tract infection, use of broad-
spectrum antibiotics such as cephalosporin, 
fluoroquinolone, hospital length of stay, live in 
nursing homes, geriatrics, and diabetes mellitus.
Long hospital length of stay especially in 
intensive care units, use of ventilator, catheter 
and use of broad-spectrum antibiotics such as 
cephalosporin.
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Carbapenem is the choice of treatment in 
critically ill patients due to ESBL-E infections, 
and usually have lower treatment failure with 
better results. Vardakas et al32 analyzed several 
studies on comparison between carbapenem 
and alternative antibiotics in treating ESBL-E 
infection, and found that empirical and definitive 
therapy with carbapenem have lower mortality 
compared to the use of combination non β-lactam 
antibiotics (non-BL) and BLI. Carbapenem, such 
as imipenem, meropenem and doripenem are 
now commonly used as empirical therapy for 
nosocomial infection due to ESBL-E.30,32-33
Infections caused by ESBL is considered as 
serious problem in treating infectious patients in 
a matter of choosing the appropriate antibiotics, 
which leads to increased use of carbapenem that 
creates new problem that is Enterobacteriaceae 
resistance to carbapenem, which of course 
will cause further difficulties in choosing 
antibiotics. In order to prevent this carbapenem 
resistance, the use of BL/BLI combination has 
come into consideration. Combination of BL/
BLI, such as amoxicillin-clavulanate (AMC) 
or piperacillin-tazobactam (PTZ) may be used 
to handle infection due to ESBL-E. Tamma et 
al34 underwent a research in the year of 2007 
until 2014 in 213 American patients that were 
divided into 2 groups, where the first group was 
given PTZ as empirical therapy then switched 
to carbapenem in 84 hours and the second group 
was treated with carbapenem from the beginning. 
A fourteen days mortality analysis was made, 
with results of higher mortality rate in the group 
initially treated with PTZ. This is different 
from a study by Rodriguez-Bano et al15 that 
analyze comparison of treatment between BL/
BLI and carbapenem to treat ESBL-EC in 2011 
in Spain among 103 patients and displayed that 
BL/BLI may be used as alternative treatment. 
Comparable results was showed by Vardakas et 
al32 dan Shiber et al35 that there is no difference in 
mortality rate between carbapenem and BL/BLI. 
Until lately, there are still limited publications 
on the use of BL/BLI in treating ESBL-E hence 
carbapenem is still considered as treatment of 
choice.30
Analyses conducted on ESBL infection 
produce variety of results. In a study by Kumar 
et al36 on 180 patients with ESBL infection in 
India, obtained that 100% cases are susceptible 
to imipenem. This study also showed ESBL 
susceptibility pattern to other anitbiotics such as 
PTZ is 87.2%, cefoperazone/sulbactam 76.7%, 
AMC 75.55%, ceftazidime/clavulanate 66.11%, 
and aminoglycoside that is amikacin 73.17% and 
gentamycin 60%.
Fosfomycin is also known to have bactericidal 
effect against Enterobacteriaceae. Falagas et 
al37 underwent a study on 4448 patients with 
ESBL-E infections and acquired that 90% cases 
are susceptible to fosfomycin. Based on CLSI 
criteria, it was mentioned that ESBL-E are 
susceptible 91.3% from 11 studies available. 
Fosfomycin given with dosage of 2-4g every 
6 hours also can be used to treat K. pneumonia 
carbapenemase (KPC) shown in a study by 
Michalopoulos et al.38 This also shown by Neuner 
et al39 in their study in 41 patients with urinary 
tract infection cased by ESBL-E or KPC, and 
found that 92% are successfully treated with 
fosfomycin.
Nitrofurantoin is considered as another choice 
of antibiotics to treat urinary tract infections 
caused by ESBL-E. In a study by Tasbakan 
et al40 showed that nitrofurantoin has good 
clinical response in patients with uncomplicated 
urinary tract infection due to ESBL-EC. In a 
study by Kulkarni et al24 toward 265 patients 
with ESBL (known from culture results), found 
that resistance test to nitrofurantoin is 75% and 
amikacin is 70.4% whereas gentamycin is only 
19.4%. However, there are not enough studies 
on the use of nitrofurantion and aminoglycoside 
in the management of ESBL-E infection hence 
they are still rarely used.
A study by Reinert et al41 as part of TEST 
study towards patients in health care centers 
of Asia Pacific, North America, America Latin 
and Europe, found that about 94.3-97.1% 
ESBL-E is susceptible to tigecycline. Whereas 
a study by Corvec et al42 mentioned that 
fosfomycin, tigecycline, and colistine can be 
use to treat ESBL, however tigecycline cannot 
be used as single antibiotic therapy to treat 
infections caused by gram-negative bacteria. If 
combined with colistine, tigecycline may give 
out better result in infection due to ESBL-KP 
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and MBL. This, of course, will make tigecycline 
a choice of treatment in managing ESBL-E 
infection. However, tigecycline is commonly 
used in treating MRSA and also infection due 
to carbapenem-resistant bacteria hence it is not 
recommended as a first line antibiotic.43
In Indonesia, Kuntaman et al44 did a study 
on susceptibility pattern of ESBL towards 
commonly used antibiotics in 300 ESBL infected 
patients in Surabaya and Malang in 2010. 
Sensitivity of ESBL-EC and ESBL-KP towards 
meropenem was 100% and 96.5% respectively, 
towards cefoperazone-sulbactam, were 97.7% 
and 94.4%, towards fosfomycin were 95.3% 
and 94.4%, towards amikacin were 90.6% and 
86.6%, towards ciprofloxacin were 26.6% and 
53.3%, whereas towards cefotaxime were 3.22% 
and 4.23% respectively. From those data, it 
can be concluded that meropenem is the main 
choice of therapy in managing infection due 
to ESBL-E, however fosfomycin, combination 
of BL/BLI and amikacin can also be used. 
Treating those patients with cephalosporin and 
fluoroquinolon should be prohibited, based on 
CLSI recommendation even if they seem to be 
sensitive in the culture results.
PREVENTION
Increasing of ESBL-E may happen easily 
within hospital environment, especially through 
medical staffs contaminated hands that will 
extent infection between patients. Distribution 
can also occur through health equipment, such 
as thermometer, endoscopy instruments and 
bath utensils. Consequently, when and how to 
perform steps of washing hands properly and 
how to sterilized medical apparatus should be 
applied in daily clinical practices. Hospitals 
have the responsibility suppress the incidence 
of ESBL-E infection one of which by isolating 
infected patients to prevent further spread.45
High prevalence of antibiotic resistance 
and inadequate choice of available antibiotics 
necessitate clinicians to use antibiotic wisely. 
Antimicrobial stewardship program (ASP) 
improve antibiotic use by shortens the duration 
of antibiotic therapy, limits the use of broad-
spectrum antibiotics and monitors appropriate 
use of antibiotic. Nowadays, Centers for 
Disease Control and Prevention (CDC) have 
recommended ASP availability in every 
hospital.46
CONCLUSION
Infection due to bacteria that resistant 
to multiple antibiotics is a rising worldwide 
problem, particularly nosocomial infection 
caused by ESBL-E. The prevalence of ESBL-E 
continues to increase, mainly in Asian countries. 
Detection of ESBL-E infection requires 
complex evaluation, consists of screening and 
confirmation. However, subtypes of ESBL-E 
keep growing thus methods available have 
become restricted; which cause detection to 
be even more challenging due to variety of 
mutations. This will of course make choosing 
antibiotic becomes problematic. Most studies 
show great results with carbapenem therapy, 
nevertheless, other antibiotics, for example BL/
BLI combination, like PTZ, and fosfomycin also 
show good results, so they can also be used to 
treat ESBL-E infection. Carbapenem should only 
be used in serious and life threatening infections 
in order to reduce carbapenem resistant, even if 
it still rarely found, particularly in Asia.
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